Hollywood star Angelina Jolie found herself at the center of an online firestorm after a new magazine photoshoot reignited ...

Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.

London man Dan Godley survived stage three pancreatic cancer with support from his fiancée, a dachshund puppy and groundbreaking treatment. He ...

A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center ...

Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to ...

The Phase 3 AMPLITUDE trial led by UCL found that adding the PARP inhibitor niraparib to standard hormone therapy may slow ...

In this retrospective study, researchers aimed to characterize persistent toxicities experienced by patients with TNBC who were treated with pembrolizumab in the curative setting.

Use of MHT following menopause is not associated with an increased risk for breast cancer among BRCA1 and BRCA2 carriers.

Men, breast cancer is a reality, not just a woman's disease. Rare but serious, it often goes undiagnosed due to lack of ...

Here are the top 5 ovarian cancer articles of 2025; stay up-to-date with all the ovarian cancer content from The American ...

TRITON3 trial data support FDA traditional approval of rucaparib for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer.

The FDA has granted full approval to rucaparib (Rubraca) for adults with BRCA-mutated metastatic castration-resistant prostate cancer. The decision is based on a confirmatory analysis of a randomized ...